Cargando…

Correction: Bromocriptine Mesylate Attenuates Amyotrophic Lateral Sclerosis: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Research in Japanese Patients

Detalles Bibliográficos
Autores principales:	Nagata, Eiichiro, Ogino, Mieko, Iwamoto, Kounosuke, Kitagawa, Yasuhisa, Iwasaki, Yasuo, Yoshii, Fumihito, Ikeda, Joh-E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4809614/ https://www.ncbi.nlm.nih.gov/pubmed/27019424 http://dx.doi.org/10.1371/journal.pone.0152845

Ejemplares similares

Bromocriptine Mesylate Attenuates Amyotrophic Lateral Sclerosis: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Research in Japanese Patients
por: Nagata, Eiichiro, et al.
Publicado: (2016)

Bromocriptine mesylate: FDA-approved novel treatment for type-2 diabetes
por: Mahajan, Rajiv
Publicado: (2009)

Effect of Bromocriptine-QR (a Quick-Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects
por: Gaziano, J. Michael, et al.
Publicado: (2012)

Effect of Bromocriptine‐QR (a Quick‐Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects
Publicado: (2015)

The therapeutic effect of bromocriptine as mesylate and estradiol valerate on serum and blood biochemistry of common quails
por: ul- Abideen, Zain, et al.
Publicado: (2021)

Neuronal apoptosis inhibitory protein is implicated in amyotrophic lateral sclerosis symptoms
por: Kano, Osamu, et al.
Publicado: (2018)

Optimization of Bromocriptine-Mesylate-Loaded Polycaprolactone Nanoparticles Coated with Chitosan for Nose-to-Brain Delivery: In Vitro and In Vivo Studies
por: Badran, Mohamed M., et al.
Publicado: (2023)

Effects of bromocriptine mesylate on homocysteine and high-sensitivity C-reactive protein levels in patients with type-2 diabetes mellitus
por: Niafar, Mitra, et al.
Publicado: (2016)

Syntactic Comprehension in Patients with Amyotrophic Lateral Sclerosis
por: Yoshizawa, Kentarou, et al.
Publicado: (2014)

Bromocriptine mesylate: Food and Drug Administration approved new approach in therapy of non-insulin dependant diabetes mellitus with poor glycemic control
por: Keche, Yogendra
Publicado: (2010)

Limb-onset amyotrophic lateral sclerosis patients visiting orthopedist show a longer time-to-diagnosis since symptom onset
por: Kano, Osamu, et al.
Publicado: (2013)

An Autopsy Case of Amyotrophic Lateral Sclerosis with Diaphragm Pacing
por: Ito, Hisashi, et al.
Publicado: (2016)

Nerve growth factor and bromocriptine: a sequential therapy for human bromocriptine-resistant prolactinomas.
por: Missale, C., et al.
Publicado: (1995)

Prediction of response to bromocriptine in acromegaly.
por: Atkinson, A. B., et al.
Publicado: (1978)

Repurposing of Bromocriptine for Cancer Therapy
por: Seo, Ean-Jeong, et al.
Publicado: (2018)

Central Hyperthermia Treated with Bromocriptine
por: Natteru, P., et al.
Publicado: (2017)

Bromocriptine, a clinical and pharmacological review /
por: Thorner, Michael O.
Publicado: (1980)

Bromocriptine in type 2 diabetes mellitus
por: Shivaprasad, C., et al.
Publicado: (2011)

Management of pituitary tumour apoplexy with bromocriptine in pregnancy
por: Janssen, Nina M, et al.
Publicado: (2012)

Bromocriptine Does Not Alter Speed–Accuracy Tradeoff
por: Winkel, Jasper, et al.
Publicado: (2012)

Bromocriptine and insulin sensitivity in lean and obese subjects
por: Bahler, L, et al.
Publicado: (2016)

Repositioning of bromocriptine for treatment of acute myeloid leukemia
por: Lara-Castillo, María Carmen, et al.
Publicado: (2016)

Effects of tolcapone and bromocriptine on cognitive stability and flexibility
por: Cameron, Ian G. M., et al.
Publicado: (2018)

Bromocriptine Use in Peripartum Cardiomyopathy: Review of Cases
por: Simon, Rebecca, et al.
Publicado: (2018)

Current treatment status and medical cost for multiple sclerosis based on analysis of a Japanese claims database
por: Ogino, Mieko, et al.
Publicado: (2016)

Repurposing bromocriptine for Aβ metabolism in Alzheimer’s disease (REBRAnD) study: randomised placebo-controlled double-blind comparative trial and open-label extension trial to investigate the safety and efficacy of bromocriptine in Alzheimer’s disease with presenilin 1 (PSEN1) mutations
por: Kondo, Takayuki, et al.
Publicado: (2021)

Bromocriptine as a new therapeutic agent for peripartum cardiomyopathy
por: Chopra, Sandeep, et al.
Publicado: (2012)

Dopaminergic Challenge With Bromocriptine in Patients With Severe Brain Injury
por: Celik, JB, et al.
Publicado: (2015)

Efficacy of bromocriptine on glycemic and metabolic control of prediabetic patients
por: Khalilzade, Saied Hossein, et al.
Publicado: (2015)

Bromocriptine inhibits proliferation in the endometrium from women with adenomyosis
por: Tang, Yiqun, et al.
Publicado: (2023)

Unilateral Measles-Associated Retrobulbar Optic Neuritis without Encephalitis: A Case Report and Literature Review
por: Hirayama, Takehisa, et al.
Publicado: (2010)

Evaluation of the efficacy and safety of bromocriptine QR in type 2 diabetes
por: Ramteke, Karuna Balwant, et al.
Publicado: (2011)

Bromocriptine Therapy for the Treatment of Invasive Prolactinoma: The Single Institute Experience
por: Cho, Kyung Rae, et al.
Publicado: (2013)

AB086. The effect of Xuanju compound capsule combined with bromocriptine
por: Bian, Jun, et al.
Publicado: (2016)

Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study
por: Hilfiker-Kleiner, Denise, et al.
Publicado: (2017)

Bromocriptine treatment in patients with peripartum cardiomyopathy and right ventricular dysfunction
por: Haghikia, Arash, et al.
Publicado: (2018)

Role of bromocriptine in multi-spectral manifestations of traumatic brain injury
por: Munakomi, Sunil, et al.
Publicado: (2017)

A Systematic Review of the Utility of Bromocriptine in Acute Peripartum Cardiomyopathy
por: Badianyama, Marheb, et al.
Publicado: (2021)

Comparison of bromocriptine and hydroxyethyl starch in the prevention of ovarian hyperstimulation syndrome
por: Zhang, Qiaoli, et al.
Publicado: (2022)

Bromocriptine monotherapy overcomes prostate cancer chemoresistance in preclinical models
por: Bai, Lijuan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_s5dd3if2ir2o9kbldrqpjii6mg